CompanyGraph
GN Store Nord A/S
GN · Nasdaq Copenhagen · Denmark
Price data from its GNc listing on CBOE
gn.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is -$1.12B, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 1.99: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
16.26BDKK2.54B · vs all stocks (USD)
Trailing P/E
50.11xvs Medical Devices peers
Revenue (TTM)
16.60BDKK2.59B · vs all stocks (USD)
Profit Margin
-2.25%vs Medical Devices peers
Beta
1.42xvs all stocks
52-Week Change
-21.22%vs all stocks
Market Capitalization
16.26BDKK2.54B · vs all stocks (USD)
Enterprise Value
23.77BDKK3.71B · vs all stocks (USD)
Trailing P/E
50.11xvs Medical Devices peers
Forward P/E
20.73xvs Medical Devices peers
Price to Sales (TTM)
0.7915xvs Medical Devices peers
Price to Book (MRQ)
1.21xvs Medical Devices peers
Enterprise to Revenue
1.43xvs Medical Devices peers
Enterprise to EBITDA
16.20xvs Medical Devices peers
Gross Margin
48.23%vs Medical Devices peers
Profit Margin
-2.25%vs Medical Devices peers
Operating Margin
-22.52%vs Medical Devices peers
Return on Assets (TTM)
2.52%vs Medical Devices peers
Return on Equity (TTM)
2.97%vs Medical Devices peers
Revenue (TTM)
16.60BDKK2.59B · vs all stocks (USD)
Revenue per Share (TTM)
113.97DKKUpdated Aug 21, 2026Quarterly Revenue Growth
-8.20%vs Medical Devices peers
Gross Profit (TTM)
9.03BDKK1.41B · vs all stocks (USD)
EBITDA (TTM)
2.70BDKK421.33M · vs all stocks (USD)
Net Income (TTM)
262.00MDKK40.95M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-58.24%vs Medical Devices peers
Operating Cash Flow (TTM)
3.06BDKK477.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.16BDKK-1.12B · vs all stocks (USD)
5-Year Average Dividend Yield
0.48%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
16.78BDKKFY2025 · Dec 31, 2025Cost of Goods Sold
7.63BDKKFY2025 · Dec 31, 2025Gross Profit
9.16BDKKFY2025 · Dec 31, 2025Operating Income
1.60BDKK249.74M · vs all stocks (USD)
Pre-tax Income
914.00MDKKFY2025 · Dec 31, 2025Income Tax Expense
204.00MDKKFY2025 · Dec 31, 2025Net Income
710.00MDKKFY2025 · Dec 31, 2025EBIT
1.31BDKKFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.38BDKKFY2025 · Dec 31, 2025Research & Development
1.46BDKKFY2025 · Dec 31, 2025Selling, General & Administrative
2.31BDKKFY2025 · Dec 31, 2025Other Operating Expenses
-9.00MDKKFY2025 · Dec 31, 2025Non-operating Interest Income
80.00MDKKFY2025 · Dec 31, 2025Non-operating Interest Expense
396.00MDKKFY2025 · Dec 31, 2025EPS (Basic)
4.48DKKFY2025 · Dec 31, 2025EPS (Diluted)
4.48DKKFY2025 · Dec 31, 2025Basic Shares Outstanding
145.61MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
145.61MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.60BDKKFY2025 · Dec 31, 2025Minority Interests (P&L)
-57.00MDKKFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00DKKFY2025 · Dec 31, 2025Operating Cash Flow
1.95BDKKFY2025 · Dec 31, 2025Free Cash Flow
1.78BDKKFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.12BDKKFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.60BDKKFY2025 · Dec 31, 2025Stock-based Compensation
-41.00MDKKFY2025 · Dec 31, 2025Other Non-cash Items
4.00MDKKFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
123.00MDKKFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
263.00MDKKFY2025 · Dec 31, 2025Capital Expenditures
-168.00MDKKFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.37BDKKFY2025 · Dec 31, 2025Net Acquisitions
-27.00MDKKFY2025 · Dec 31, 2025Other Investing Activity
-45.00MDKKFY2025 · Dec 31, 2025Net Investing Cash Flow
-240.00MDKKFY2025 · Dec 31, 2025Long-term Debt Issuance
7.70BDKKFY2025 · Dec 31, 2025Long-term Debt Payments
-8.07BDKKFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-258.00MDKKFY2025 · Dec 31, 2025Common Dividends Paid
-85.00MDKKFY2025 · Dec 31, 2025Other Financing Charges
-37.00MDKKFY2025 · Dec 31, 2025Net Financing Cash Flow
-751.00MDKKFY2025 · Dec 31, 2025Shares Outstanding
145.61MSharesUpdated Aug 21, 2026Float Shares
145.41MSharesUpdated Aug 21, 2026% Held by Insiders
0.00%vs all stocks
% Held by Institutions
35.13%vs all stocks
Total Cash (MRQ)
865.00MDKK135.18M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.94DKKUpdated Aug 21, 2026Total Debt (MRQ)
9.96BDKK1.56B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9840xvs Medical Devices peers
Current Ratio (MRQ)
2.00xvs Medical Devices peers
Book Value per Share (MRQ)
74.84DKKUpdated Aug 21, 2026Total Assets
29.23BDKK4.57B · vs all stocks (USD)
Total Current Assets
8.64BDKKFY2025 · Dec 31, 2025Total Liabilities
18.33BDKKFY2025 · Dec 31, 2025Total Non-current Assets
20.59BDKKFY2025 · Dec 31, 2025Total Non-current Liabilities
11.01BDKKFY2025 · Dec 31, 2025Total Current Liabilities
7.32BDKKFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.12BDKKFY2025 · Dec 31, 2025Accounts Receivable
4.38BDKKFY2025 · Dec 31, 2025Inventory
2.31BDKKFY2025 · Dec 31, 2025Accounts Payable
1.50BDKKFY2025 · Dec 31, 2025Short-term Debt
1.92BDKKFY2025 · Dec 31, 2025Other Current Liabilities
3.50BDKKFY2025 · Dec 31, 2025Long-term Debt
8.89BDKKFY2025 · Dec 31, 2025Other Non-current Liabilities
904.00MDKKFY2025 · Dec 31, 2025Common Stock (Book)
604.00MDKKFY2025 · Dec 31, 2025Retained Earnings
14.27BDKKFY2025 · Dec 31, 2025Total Shareholders' Equity
10.90BDKK1.70B · vs all stocks (USD)
Treasury Stock
2.73BDKKFY2025 · Dec 31, 202552-Week Low
85.12DKKUpdated Aug 21, 202652-Week High
125.90DKKUpdated Aug 21, 202652-Week Change
-21.22%vs all stocks
Beta
1.42xvs all stocks
50-Day MA
93.18DKKUpdated Aug 21, 2026200-Day MA
98.92DKKUpdated Aug 21, 2026Avg 10-Day Volume
637.52KSharesUpdated Aug 21, 2026Avg 30-Day Volume
525.18KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.80DKKUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.48Profit Margin: -0.02
Financial Health
Altman Z-Score 1.99: grey zoneSignificant
Altman Z-Score: 1.99
High earnings qualityNotable
Earnings Quality Score: 0.55
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is -$1.12B, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -1,118,925,752.504Global P5: -219,013,500
Market cap is $2.54B, above the global median of $1.15BNotable
Market cap (USD): 2,541,881,739.952Global Median: 1,146,734,693.424
Revenue is $2.59B, above the global median of $520.53MNotable
Revenue (USD): 2,593,466,650.01Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule